Delivery Order SPE2DR25D2014-SPE2DR26FZ66M
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,554.67 and an ultimate completion date of November 10, 2025. This is a firm fixed-price, non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be...
- On July 22, 2025, the Defense Logistics Agency awarded a delivery order contract valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by July 23, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,017.61 on November 5, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract utilizes firm fixed pricing with no set-aside designation and is expected to be completed by November 6, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime contract vehicle designated...
- The Defense Logistics Agency awarded a delivery order valued at $4,498.99 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price contract was issued on September 18, 2025, with an ultimate completion date of September 19, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce...
- The Defense Logistics Agency awarded a $7,931.56 delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This is a firm fixed price, non-set-aside contract with an ultimate completion date of November 5, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol levels in patients with cardiovascular disease,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,922.90 firm fixed-price delivery order for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of November 6, 2025. This competitively awarded contract, issued on November 5, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency's Medical Supply Chain awarded a $41,519.06 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price, non-set-aside contract is expected to be completed by September 22, 2025, with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. Repatha is a PCSK9 inhibitor used to reduce LDL cholesterol levels and is essential for...
- The Defense Logistics Agency awarded a delivery order valued at $6,948.71 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 5, 2025. This non-competitive, firm fixed-price delivery order was issued on November 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA's Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,188.10 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate office...
- AmerisourceBergen Drug Corp was awarded a delivery order on November 4, 2025, by the Defense Logistics Agency for the supply of Repatha 140 mg/ml SureClick auto-injectors. This is a competitively awarded, firm fixed-price delivery order with a ceiling value of $15,222.77 and an ultimate completion date of November 5, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ66MDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Repatha 140 mg/mL SureClick autoinjectors, valued at $20,864.65 with a firm fixed price structure. The contract is non-set-aside and competitively awarded, with an ultimate completion date of November 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha is a cardiovascular therapy used for cholesterol management, representing one of the specialized medications within the company's extensive federal contract portfolio that includes biologics, brand-name and generic pharmaceuticals, and medical devices supporting multiple therapeutic domains across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.9k | 11/7/25 |